AC Immune (ACIU) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
BenzingaSep 23 05:46 ET
AC Immune SA Welcomes New CMO Dr. Anke Post
TipRanksSep 19 16:58 ET
BTIG Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsSep 18 07:31 ET · Ratings
AC Immune Analyst Ratings
BenzingaSep 18 06:31 ET · Ratings
H.C. Wainwright Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsSep 18 06:31 ET · Ratings
Analyst Issues Buy Rating for AC Immune SA on Promising Alzheimer's Treatment Prospects
TipRanksSep 18 06:16 ET · Ratings

Comments

amiable Hedgehog_758

Sep 17 06:34

$AC Immune (ACIU.US)$
AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
Benzinga· 10 mins ago5mins
AC Immune (ACIU.US)
3.270
3.530
+2.83%
+7.95%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...

1

Trytosaveabit

Sep 17 06:09

News

$AC Immune (ACIU.US)$ Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
Dow Jones· 7 mins ago
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

1

Jaguar8

Sep 17 06:02

NEWS

$AC Immune (ACIU.US)$
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially regist...

Jaguar8

Aug 28 08:31

NEWS

$AC Immune (ACIU.US)$
AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan
AC Immune's partner, Life Molecular Imaging (LMI), has received Fast Track Designation from the FDA for the Tau-PET diagnostic [18F]PI-2620 in three neurodegenerative conditions: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). PI-2620, currently in Phase 3 clinical development for detecting Tau pathology in AD, is a next-generation PET imag...

Trytosaveabit

Jul 25 06:20

Update

$AC Immune (ACIU.US)$ AC Immune Says Active-Immunotherapy Candidate, ACI-35.030 (Now Called JNJ-2056), Targeting Pathologic Form Of Tau Protein Has Received Fast Track Designation From FDA

1

5

ACIU AC Immune

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target